Claritas Pharmaceuticals Management
Management criteria checks 3/4
Claritas Pharmaceuticals' CEO is Bob Farrell, appointed in Jul 2016, has a tenure of 6.25 years. directly owns 0.26% of the company’s shares, worth CA$2.47K. The average tenure of the management team and the board of directors is 5.8 years and 5.1 years respectively.
Key information
Bob Farrell
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 6.3yrs |
| CEO ownership | 0.3% |
| Management average tenure | 5.8yrs |
| Board average tenure | 5.1yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2021 | n/a | n/a | US$2m |
| Jun 30 2021 | n/a | n/a | US$2m |
| Mar 31 2021 | n/a | n/a | -US$12m |
| Dec 31 2020 | US$300k | US$300k | US$4m |
| Sep 30 2020 | n/a | n/a | -US$7m |
| Jun 30 2020 | n/a | n/a | -US$8m |
| Mar 31 2020 | n/a | n/a | -US$875k |
| Dec 31 2019 | US$300k | US$300k | -US$21m |
| Sep 30 2019 | n/a | n/a | -US$12m |
| Jun 30 2019 | n/a | n/a | -US$9m |
| Mar 31 2019 | n/a | n/a | US$2m |
| Dec 31 2018 | US$300k | US$300k | US$7m |
| Sep 30 2018 | n/a | n/a | -US$21m |
| Jun 30 2018 | n/a | n/a | -US$24m |
| Mar 31 2018 | n/a | n/a | -US$32m |
| Dec 31 2017 | US$300k | US$300k | -US$32m |
| Sep 30 2017 | n/a | n/a | -US$14m |
| Jun 30 2017 | n/a | n/a | -US$13m |
| Mar 31 2017 | n/a | n/a | -US$13m |
| Dec 31 2016 | US$174k | US$174k | -US$12m |
Compensation vs Market: Insufficient data to establish whether Bob's total compensation is reasonable compared to companies of similar size in the Canadian market.
Compensation vs Earnings: Bob's compensation has been consistent with company performance over the past year.
CEO
Bob Farrell
6.3yrs
Tenure
US$300,000
Compensation
Mr. Robert Farrell, also known as Bob, J.D., serves as the President of Claritas Pharmaceuticals, Inc. (formerly Kalytera Therapeutics, Inc.) and has been its Chief Executive Officer since October 10, 2017...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 6.3yrs | US$300.00k | 0.26% $ 2.5k | |
| Interim CFO | 7.6yrs | US$75.00k | no data | |
| Co-Founder | no data | US$22.50k | no data | |
| Co-Chair of Scientific Advisory Board and Vice President of Medical Affairs | no data | no data | no data | |
| Chief Scientific Officer | 5.3yrs | US$212.00k | no data | |
| Chief Medical Officer | 5.3yrs | US$162.00k | no data | |
| Head of Chemistry | no data | no data | no data |
5.8yrs
Average Tenure
54yo
Average Age
Experienced Management: CLAS's management team is seasoned and experienced (5.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 5.8yrs | US$300.00k | 0.26% $ 2.5k | |
| Co-Chair of Scientific Advisory Board and Vice President of Medical Affairs | 7yrs | no data | no data | |
| Member of Scientific Advisory Board | 6.3yrs | no data | no data | |
| Scientific Advisor | no data | US$596.03k | no data | |
| Co-Chair of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Strategic & Scientific Advisory Board | 4.4yrs | no data | no data | |
| Independent Director | 1.6yrs | no data | no data | |
| Independent Director | 1.6yrs | no data | no data |
5.1yrs
Average Tenure
73yo
Average Age
Experienced Board: CLAS's board of directors are considered experienced (5.1 years average tenure).